Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis

Affiliations

• ¹ Cardiovascular Imaging Research Center, Division of Cardiology and Department of Radiology (L. Zhang, M.A., M.Z.O.H., R.M.A., A.R., T.G.N.), Massachusetts General Hospital, Boston.
• ² Cardio-Oncology Program, Division of Cardiology, Department of Medicine (L. Zhang, D.A.Z., M.A., S.P.M., M.J.-O., T.G.N.), Massachusetts General Hospital, Boston.
• ³ Cardiology Division, New York-Presbyterian Hospital, Weill Cornell Medical Center (S.S.M.).
• ⁴ Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA (A.N., J.D.G.).
• ⁵ Aix-Marseille University, Assistance Publique - Hôpitaux de Marseille, University Mediterranean Center of Cardio-Oncology, Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Nord Hospital, Center for Cardiovascular and Nutrition Research, France (F.T.).
• ⁶ Mediterranean Group of Cardio-Oncology, Marseille, France (F.T.).
• ⁷ Division of Oncology and Hematology, Department of Medicine (L. Zubiri, R.J.S., J.V.C., K.L.R.), Massachusetts General Hospital, Boston.
• ⁸ Cardiology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York (C.LC., D.G.).
• ⁹ Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Germany (L.M.H., M.C.K.).
• ¹⁰ Cardio-Oncology Program, MedStar Heart and Vascular Institute, Georgetown University, Washington, DC (A.B., B.J.F.).
• ¹¹ UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine, University of California at Los Angeles (E.H.Y.).
• ¹² Cardiology Division, Lahey Hospital and Medical Center, Burlington, MA (S.P.S., S.G.).
• ¹³ Division of Oncology and Hematology, Department of Medicine, Lehigh Valley Hospital, Allentown, PA (M.A.R.).
• ¹⁴ Mount Sinai Hospital, New York (G.S.).
• ¹⁵ Cardio-Oncology Program, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA (A.M.).
• ¹⁶ Faculty of Medicine, University of Southampton, United Kingdom (M.M.).
• ¹⁷ AP-HP, Saint-Antoine Hospital, Department of Cardiology, UNICO-GRECO Cardio-Oncology Program, Paris, France (S.E.).
• ¹⁸ Service of Cardiology, General University Hospital Gregorio Marañón, Madrid, Spain (E.Z.-N.).
• ¹⁹ Department of Translational Medical Sciences, Federico II University, Naples, Italy (C.G.T.).
• ²⁰ Cardio-Oncology Program, Royal Brompton Hospital, and Imperial College London, United Kingdom (A.R.L.).
• ²¹ Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, Division of Cardiology, Toronto General Hospital, University of Toronto, Ontario, Canada (P.T.).
• ²² Cardio-Oncology Program, Division of Cardiovascular Medicine, Department of Medicine, University of Pennsylvania, Philadelphia (M.G.F.).